Management of the Patient with Heart Failure and an Implantable Pulmonary Artery Hemodynamic Sensor
Current Cardiovascular Risk Reports
Purpose of Review
Heart failure (HF) management guided by hemodynamics obtained from an implantable pulmonary artery pressure (PAP) sensor (CardioMEMS) improves symptoms and reduces HF hospitalizations (HFH). This paper reviews the theoretical basis of pulmonary vascular physiology, summarizes recently published data about CardioMEMS, and provides practical guidelines for patient selection and management.
Compared to patients managed by standard care, HF patients randomized to PAP-guided treatment have a higher frequency of medication adjustments, resulting in lower PAP and fewer HFH. Real-world analyses further support associations between implant of the CardioMEMS sensor with reductions in PAP, hospitalizations, and mortality.
Implantable, wireless hemodynamic sensor technology is a promising remote monitoring platform for chronic HF. A phased approach using a treatment algorithm may improve the efficiency and effectiveness of pressure-guided therapy.
Center for Cardiovascular Analytics, Research + Data Science (CARDS)
Abraham, Jacob; McCann, Patrick J.; Guglin, Maya E.; Bhimaraj, Arvind; Benjamin, Terrie-Ann S.; Robinson, Monique R.; Jonsson, Orvar T.; Feitell, Scott C.; Bhatt, Kunjan A.; Bennett, Mosi K.; Heywood, JT; and Hemodynamic Frontiers in Heart Failure (HF2) Investigators, "Management of the Patient with Heart Failure and an Implantable Pulmonary Artery Hemodynamic Sensor" (2020). Articles, Abstracts, and Reports. 3437.